FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular to a specific variant III of the epidermal growth factor receptor (EGFRvIII), a chimeric antigen receptor (CAR) containing an EGFRvIII-binding domain, a transmembrane domain and an intracellular signaling domain, as well as a polynucleotide encoding it. Also disclosed is a vector, a cell containing the above-mentioned polynucleotide. The invention also relates to an immune cell containing the above-mentioned polynucleotide, a method for its preparation, as well as a pharmaceutical composition containing it.
EFFECT: invention makes it possible to effectively treat cancer.
17 cl, 9 dwg, 10 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| T- CELLS WITH COSTIMULATING CHIMERIC ANTIGEN RECEPTOR TARGETING IL13Rα2 | 2015 |
|
RU2749922C2 |
| ANTI-CLL1-SPECIFIC SINGLE-CHAIN CHIMERIC ANTIGENIC RECEPTORS (SCCAR) FOR CANCER IMMUNOTHERAPY | 2016 |
|
RU2731543C2 |
| CD123-SPECIFIC CHIMERIC ANTIGENIC RECEPTORS FOR CANCER IMMUNOTHERAPY | 2015 |
|
RU2727290C2 |
| ISOLATED ALTERNATIVE INTRACELLULAR SIGNALLING DOMAIN OF CHIMERIC ANTIGEN RECEPTOR AND CHIMERIC ANTIGEN RECEPTOR INCLUDING IT | 2019 |
|
RU2742000C2 |
| TREATMENT OF MALIGNANT NEOPLASM USING HUMANIZED CHIMERIC ANTIGEN RECEPTOR AGAINST BCMA | 2015 |
|
RU2751660C2 |
| COMPOSITIONS AND LIBRARIES CONTAINING RECOMBINANT POLYNUCLEOTIDES ENCODING T-CELL RECEPTORS AND METHODS FOR USING RECOMBINANT T-CELL RECEPTORS | 2017 |
|
RU2752528C2 |
| CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF | 2014 |
|
RU2727447C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETING CD70 | 2019 |
|
RU2801824C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETING HER2 | 2016 |
|
RU2753695C2 |
| NEW CHIMERIC ANTIGEN RECEPTOR CONSTRUCTS CONTAINING TNFR2 DOMAINS | 2019 |
|
RU2808254C2 |
